Novel DNRI Agent Improves ADHD Symptoms in Study
MPR > News > Drugs In The Pipeline > Novel DNRI Agent Improves ADHD Symptoms In Study Da Hee Han, PharmD April 21, 2017 Sunovion announced positive Phase 3 study data (SEP360-305) for dasotraline being evaluated in patients aged 6–12 years with attention deficit hyperactivity disorder (ADHD). The findings were presented at the 6th World Congress on ADHD in…